Market Updates

Trygg Pharma to Start Clinical Study

Trygg Pharma, Inc., a subsidiary of Aker BioMarine, Oslo, Norway, is currently enrolling patients in its clinical trial, a Phase III clinical study assessing the efficacy of AKR 963—an investigational candidate drug developed by the company—for treating patients with severe hypertriglyceridemia.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters